Optain raises $13M to expand AI eye-screening tech
What's the deal? Optain, a retinal diagnostics startup also known as Eyetelligence, has raised $13 million in an early-stage round. Morningside, Insight Partners, and UniQuest Extension FundDealroom has a profile for this one. Try Dealroom → backed the deal.
What's the endgame? Led by chief executive officer Jeff Dunkel, Optain is building AI software that screens for eye disease — detecting glaucoma, age-related macular degeneration, and diabetic retinopathy — as well as cardiovascular risk. It plans to use the funds to expand operations and development.
Why it matters: The round ranks among the largest early-stage health deals in Australia, sitting in the 96th percentile of all comparable rounds on record.
The signal: Investor appetite for AI diagnostics that turn a single retinal scan into multiple health readouts continues to build, pulling in backers from both the US and Australia.
Read more: finsmes.com
Image credit: "DA-ST-86-05893" by expertinfantry, licensed under CC BY 2.0